Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 6/20 | 0.75 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 6/20 | 0.33 |
| ▸ | TMPRSS15 | P98073 | 4/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30398815 | 1.00 | ADRA2C (0.75) | ADRA2CHRH3MAPK8TMPRSS15ITGB3 | |
| SCHEMBL29787275 | 1.00 | ADRA2C (0.75) | ADRA2CHRH3MAPK8TMPRSS15ITGB3 | |
| SCHEMBL29787286 | 0.90 | ADRA2C (0.75) | ADRA2CHRH3MAPK8TMPRSS15ITGB3 | |
| SCHEMBL24183541 | 0.90 | ADRA2C (0.75) | ADRA2CHRH3MAPK8TMPRSS15ITGB3 | |
| SCHEMBL24183463 | 0.90 | ADRA2C (0.83) | ADRA2CHRH3MAPK8TMPRSS15ITGB3 | |
| SCHEMBL29787254 | 0.90 | ADRA2C (0.83) | ADRA2CHRH3MAPK8TMPRSS15ITGB3 | |
| SCHEMBL24183636 | 0.90 | ADRA2C (0.74) | ADRA2CHRH3MAPK8TMPRSS15ITGB3 | |
| SCHEMBL30398477 | 0.90 | ADRA2C (0.74) | ADRA2CHRH3MAPK8TMPRSS15ITGB3 | |
| SCHEMBL29787289 | 0.90 | ADRA2C (0.74) | ADRA2CHRH3MAPK8TMPRSS15ITGB3 | |
| SCHEMBL24183645 | 0.89 | ADRA2C (0.79) | ADRA2CHRH3MAPK8TMPRSS15ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023118123-A1 | COMBINATION OF AN Α2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A NOREPINEPHRINE REUPTAKE INHIBITOR FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023118098-A1 | COMBINATION OF AN α2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS WITH A MUSCARINIC RECEPTOR ANTAGONIST FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-29 | — | — | WO | disclosed |
| CN-116057057-A | Conjugates of alpha 2-adrenoceptor subtype C (alpha-2C) antagonists and TASK1/3 channel blockers for the treatment of sleep apnea | 拜耳公司 | 2023-05-02 | — | — | CN | disclosed |
| US-20230115270-A1 | INHIBITORS OF ADRENORECEPTOR ADRAC2 | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| CN-114929694-A | Adrenergic receptor ADRAC2 antagonists | 拜耳公司 | 2022-08-19 | — | — | CN | disclosed |
| WO-2022008426-A1 | COMBINATION OF AN ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2022-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230115270-A1 | INHIBITORS OF ADRENORECEPTOR ADRAC2 | ADRA2C, ADRB2, ADRB3 | ADRA2C 1/4885HRH3 55/4885MAPK8 1728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.